FDA's ODAC will review drugs for four different cancers at meeting in May
The FDA announced a two-day meeting of its Oncologic Drugs Advisory Committee (ODAC) later this month to review four cancer drugs …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
